Grover disease: review of subtypes with a focus on management options.

Grover disease (GD) is a benign eruption that causes a papulovesicular rash on the trunk and proximal extremities. It often resolves spontaneously but can follow a more chronic and fluctuating course that may last several years. Although the etiology remains unknown, several associated triggers have been identified including heat and sweating, cool and dry air, renal failure, malignancy, and the initiation of several drugs. Since the disease tends to resolve on its own, management is aimed at disease prevention and symptomatic relief. First-line therapy includes topical steroids and vitamin D analogues with adjuvant antihistamines. In more severe cases that are refractory to less aggressive therapy, systemic corticosteroids, retinoids, and phototherapy may lead to successful resolution. Novel therapies are few and have little evidence but involve innovative use of light therapy and immune modulators. Herein, we review the literature and new trends of GD with a focus on established and novel treatments.

Dermatosis perforantes: presentación de 8 casos / Perforating dermatosis: report of 8 cases

Las dermatosis perforantes (DP) o enfermedades por eliminación transepidérmica son un grupo de entidades caracterizadas por la extrusión de material dérmico alterado a través de la epidermis que incluye a la colagenosis perforante reactiva, la elastolisis perforante serpiginosa, la foliculitis perforante y la enfermedad de Kyrle. Se caracterizan por la aparición de pápulo-nódulos centrados por tapones o costras queratósicas, pruriginosos. Entre las opciones terapéuticas se describen los antihistamínicos, fototerapia y corticoides intralesionales, con resultados variables. Objetivos. Describir 8 casos de dermatosis perforante diagnosticados en nuestro servicio. Materiales y Métodos. Se realizó un estudio retrospectivo, observacional y descriptivo que evaluó las características clínicas, histológicas y la asociación con patología sistémica de los pacientes con diagnóstico histológico de dermatosis perforante que concurrieron a nuestro servicio entre septiembre de 2006 y julio de 2010.Resultados. Se diagnosticaron 8 pacientes con dermatosis perforante. Del total, 5 (62,5%) fueron hombres y 3 mujeres (37,5%). La edad media de presentación fue de 57,12 años (37-71 años); 6 (75%) correspondían a enfermedad de Kyrle y 2 (25%) a foliculitis perforante; 6 (75%) se asociaban a insuficiencia renal crónica, 6 (75%) a diabetes mellitus, 1 (12,5%) a insuficiencia renal aguda y 6 (75%) a enfermedad cardiovascular. Conclusiones. Si bien la mayoría de nuestros pacientes tenían antecedentes de diabetes y/o insuficiencia renal crónica como se describe en la literatura, cabe destacar que en uno de ellos no se encontró ninguna de estas asociaciones. Adicionalmente, el 75% de los pacientes tenía antecedentes de enfermedad cardiovascular. Encontramos una mayor incidencia en hombres (62,5%) a diferencia de lo reportado en algunos trabajos (AU)

Perforating dermatosis (DP) comprises a group of diseases characterized by the extrusion of dermic debris through the epidermis. It includes reactive perforating collagenosis, perforating folliculitis, elastosis perforans serpiginosa and Kyrle's disease. It presents as multiple pruritic papulo nodules centered by a keratotic plug. Antihistamines, phototherapy and intralesional steroids are among the therapeutic options described, with variable results. Objectives. To describe 8 cases of perforating dermatosis diagnosed in our department. Materials and Methods. We conducted a retrospective, observational and descriptive study evaluating clinical and histological features and association with systemic disease, of the patients with a biopsy confirmed, perforating dermatosis between September 2006 and July 2010. Results. Eight patients with perforating dermatosis were diagnosed. Of them, 5 (62,5%) were male and 3 female (37,5%). Mean age of presentation was 57,12 years (37-71 years); 6 (75%) corresponded to Kyrle's disease and 2 (25%) to perforating folliculitis; 6 (75%) were associated with chronic renal insufficiency, 6 (75%) with diabetes mellitus, 1 (12,5%) with acute renal insufficiency and 6 (75%) with cardiovascular disease. Conclusions. Although most of our patients had a history of chronic renal insufficiency or diabetes, as described in the literature, in one of them no associated disease was found. Furthermore, 75% of the patients presented with cardiovascular disease. Unlike previous reports, we found agreater incidence in men (62,5%) over women (AU)

Percepción del médico y paciente de la gravedad de la psoriasis, su impacto en la calidad de vida y satisfacción con la atención y el tratamiento recibido. Estudio observacional en España / Physician and Patient Perception of Disease Severity, Quality of Life, and Treatment Satisfaction in Psoriasis: An Observational Study in Spain

Introducción: El objetivo de este estudio fue evaluar el impacto de la psoriasis en la calidad de vida del paciente, las diferencias entre médicos y pacientes en las percepciones sobre la calidad de vida, los tratamientos y las necesidades de los pacientes y la relación médico-paciente. Material y métodos: Estudio observacional, multicéntrico, de corte transversal, en el cual un grupo de dermatólogos representativos de toda la geografía española, con ejercicio tanto en el ámbito hospitalario como ambulatorio, y de pacientes con diagnóstico de psoriasis, cumplimentaron una encuesta especialmente diseñada para el estudio. La encuesta incluía preguntas sobre datos demográficos del paciente, características de la enfermedad, impacto de esta sobre la calidad de vida, manejo terapéutico de la psoriasis y relación paciente-dermatólogo. Resultados: Un total de 151 dermatólogos de toda España incluyeron una media de 5 pacientes cada uno. Se incluyeron en el análisis un total de 771 encuestas cumplimentadas por los dermatólogos y 732 encuestas cumplimentadas por los pacientes. Dos terceras partes de los pacientes presentaban una enfermedad moderada a grave con una importante repercusión en la calidad de vida, en especial sobre el estado emocional. No obstante, la calidad de vida sóloe ra evaluada de forma sistemática y rutinaria por el 19,9% de los dermatólogos. El 47% de los pacientes estaba muy satisfecho o bastante satisfecho con el tratamiento que recibía. No se encontraron diferencias relevantes entre las percepciones del paciente y del médico sobre los aspectos evaluados. Conclusiones: Nuestros resultados señalan el importante impacto que tiene la psoriasis sobre la calidad de vida del paciente y la necesidad de evaluar este parámetro de forma sistemática. Los pacientes refieren un buen grado de satisfacción con la atención recibida por los dermatólogos y los tratamientos administrados. Existe bastante concordancia entre los pacientes y los dermatólogos en la valoración de los parámetros evaluados (AU)

Objectives: The aims of this study were to determine the impact of psoriasis on patient quality of life, to analyze differences in perception between patients and physicians regarding quality of life, treatment satisfaction, and patient needs, and to assess the physician—patient relationship. Material and methods: A multicenter, observational, cross-sectional study was undertaken in which a representative group of dermatologists—–working in hospitals and outpatient clinics throughout Spain—–and their patients with a diagnosis of psoriasis completed specifically designed questionnaires. The questionnaires covered patient demographics, disease characteristics, impact of the disease on quality of life, treatment of psoriasis, and the relationship between patient and dermatologist. Results: A total of 151 dermatologists from throughout Spain included a mean of 5 patients each. The analysis included 771 questionnaires completed by dermatologists and 732 completed by patients. Two-thirds of patients had moderate-to-severe psoriasis with a major impact on quality of life, particularly in relation to emotional wellbeing. Nevertheless, quality of life was only assessed routinely and systematically by 19.9% of dermatologists. Overall, 47% of patients reported being quite satisfied or very satisfied with the treatment they received. No significant differences were observed between patients and dermatologists on the aspects analyzed. Conclusions: Our results highlight the substantial impact of psoriasis on patient quality of life and the consequent need for systematic quality-of-life assessment in affected patients. Patients reported a high level of satisfaction with the care provided by dermatologists and the treatment received. There was good agreement between patients and dermatologists in their assessment of the variables analyzed (AU)

[Pulsed dye laser treatment for Jessner's lymphocytic infiltration of the skin]. / Infiltrat lymphocytaire de Jessner et Kanof traité par laser à colorant pulsé

BACKGROUND: Jessner's lymphocytic infiltration of the skin (LIS) is a chronic, benign T-cell infiltrative disorder, usually manifesting as erythematous papules or plaques on the face, neck and back. PATIENTS AND METHODS: five patients presented LIS with numerous skin lesions on the face and back characteristic of this disease. Histological examination showed a lymphocytic infiltrate in the dermis without any modification of the epidermis. Direct immunofluorescent study was negative in all cases. Response to dermocorticoids proved inconsistent or negative in all patients. An excellent outcome was achieved in all five patients with pulsed dye laser. In one case, further skin lesions appeared at 1 year and responded to the same treatment. Following a single treatment session with 6-8 J/cm(2), three of five patients showed normal skin. Regression occurred in the other two cases after two to three sessions. Pulsed dye laser appeared to be the best treatment for Jessner-Kanof disease for three patients at 4-8 years of follow-up. DISCUSSION: only one case of Jessner-Kanof disease treated by pulsed dye laser has been reported. Pulsed dye laser has been used in cutaneous lupus and annular granuloma. Selective photothermolysis allows photocoagulation of dilated vessels. CONCLUSION: pulsed dye laser at 595nm could offer a valuable therapeutic alternative, and even a first-line treatment with no side effects.

Mycosis fungoides presenting as Ofuji's papuloerythroderma.

We report three patients presented with clinical features of Ofuji's papuloerythroderma (pruritic erythematous papules and extensive erythema sparing all skin folds), however, showing histopathological findings of mycosis fungoides (Pautrier's microabscess, haloed lymphocytes, disproportionate epidermotropism, and wiry collagen bundles). One case was associated with plaque stage of mycosis fungoides and follicular mucinosis. T-cell receptor (TCR) gene rearrangement analysis in the lesional skin tissue demonstrated rearrangement of the gamma chain in all cases. HTLV-1 serology was negative for two patients who conducted HTLV-1 test. We think that Ofuji's papuloerythroderma might be a variant of early mycosis fungoides rather than secondary skin manifestations to certain cutaneous inflammatory diseases.

Can the immersion time of PUVA bath therapy be shortened?

Up to now, there are only a few data available concerning the influence of bathing time on skin phototoxicity. We compared the erythemal responses of normal skin to bath PUVA with 8-methoxypsoralen (8-MOP) after 5, 10 and 20 min immersion time. Currently, 20 min is the routinely performed immersion time in many European countries, including Germany, while in other countries bathing times are shorter. The minimal phototoxic dose (MPD) following immersion times of 5 min and 10 min in a warm water bath (37 degrees C) containing 1 mg/l 8-MOP was compared to the MPD following 20 min immersion time in a half-sided manner in a total of 24 patients. Our results revealed that an immersion time of 5 min did not yield a detectable erythema after 72 h. In contrast, both 10 and 20 min PUVA baths induced visible erythemas with a significantly higher median MPD following 10 min immersion (2.25 J/cm2) compared to 20 min baths (1.5 J/cm2). As an erythemal response of 8-MOP PUVA bath seems reduced after shorter immersion times, comparative studies on the clinical efficacy using shorter time regimens have to be conducted before conclusive recommendations for clinical PUVA-bathing time can be given.

Evaluation and treatment of itching in HIV-infected patients.

Itching is a common complaint among patients infected with HIV and may cause significant morbidity and embarrassment. Although idiopathic HIV-pruritus has been described, it is probably less common than was previously thought. In most patients, a careful history and physical examination will show that a dermatosis accounts for their pruritus. Dry skin, seborrheic dermatitis, eczema, psoriasis, pruritic papular eruption, staphylococcal folliculitis and prurigo nodularis are frequently encountered in these patients. These common dermatoses, drug eruptions, several rarer conditions and systemic causes of itching should be excluded before diagnosing idiopathic HIV-pruritus. Treatment should be directed to the underlying skin problem and may be supplemented with sedating antihistamines. Phototherapy is a safe and effective therapeutic modality for many pruritic dermatoses as well as for idiopathic pruritus.

[UV-therapy in HIV-infected patients]. / UV-Therapie bei HIV-Patienten.

We examined the prevalence of HIV-associated cutaneous disorders as well as the frequency and efficiency of UV-radiation in HIV-infected patients by evaluating the clinical records of 1310 patients seen between and 1994 and 1996. 41 patients were treated with UVB-radiation and 4 patients with UVA1-radiation, while three patients received PUVA-therapy. UV-radiation proved to be efficient and safe in the treatment of pruritic papular eruption, atopic dermatitis and psoriasis. Although some in vitro studies and studies with transgenic mice have suggested a negative impact of UV radiation on the immunosystem of HIV-positive patients, no progression of the HIV infection due to phototherapy has been proven.

[Ofuji papuloerythroderma: PUVA bath treatment]. / Papuloerythroderma Ofuji: Bade-PUVA-Behandlung.

Papuloerythroderma of Ofuji is a rare skin disorder described primarily in Japanese patients. It occurs primarily in elderly men. The initial lesions are diffuse red papules, sparing the face, palms and soles. Later the papules coalesce into an erythroderma, with typical sparing of the skin folds and creases (the deck chair sign). Pruritus is usually intense. Lymphadenopathy, peripheral blood eosinophilia and elevated IgE levels all are common. Both systemic corticosteroids and systemic PUVA therapy have been recommended. We describe a German male who fulfilled the diagnostic criteria for papuloerythroderma of Ofuji and responded well to PUVA bath therapy with both improvement in skin findings and reduction in pruritus.

Lichen amyloidosis presenting as a papular pruritus syndrome in a human-immunodeficiency-virus-infected man.

A human-immunodeficiency-virus (HIV)-positive man presented with pruritic erythematous and flesh-colored papules on his arms and trunk of 1 year's duration. The lesions had previously been treated with oral ketoconazole and topical emollients with no improvement. Microscopic evaluation of lesional skin from his left forearm showed lichen amyloidosis. The patient was started on ultraviolet B phototherapy which he received for 2 weeks without improvement. Lichen amyloidosis should be added to the differential diagnosis of papular pruritus syndrome in HIV-positive individuals.